Citigroup Maintains Buy on Krystal Biotech, Raises Price Target to $386
Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $378 to $386.
Read original at benzingaStocks · News reference
RBC Capital Initiates Coverage On Krystal Biotech with Outperform Rating, Announces Price Target of $400
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 14, 2026, 2:15 PM
- Checked
- Aug 14, 2026, 2:15 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Krystal Biotech shares are trading lower after the company announced mixed Q2 financial results.
Read original at benzinga8-K filing — Krystal Biotech, Inc. (KRYS)
Filed: 2026-08-03 AccNo: 0001711279-26-000058 Size: 587 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar